Figure 6.

Ser239 phosphorylation of VASP is required for the effects of DDAH on ADMA-treated cells. PAECs expressing WT GFP-VASP, the nonphosphorylatable mutant of VASP (S239A GFP-VASP), or the phosphomimetic mutant of VASP (S239D GFP-VASP) were left untreated, were treated with ADMA, or were overexpressed DDAHI. (A) Effects of VASP mutants on FITC-dextran flux in PAECs; n = 5. * p < 0.05, ** p < 0.01, comparison with untreated controls; ^# p < 0.05, ^## p < 0.01, comparison with ADMA-treated cells. (B) The effects of VASP mutants on F-actin and VE-cadherin in recently confluent cells, as indicated. Bar, 10 μm. (C) Changes in Rac1 activity in PAECs overexpressing VASP mutants, whereas corresponding Western blots are shown in D. (E) Equal expression of VASP-GFP mutants in PAECs is shown.